news
Enspryng® prevents relapse in over 70 percent of NMOSD patients
Enspryng (satralizumab) significantly reduced relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) in Phase III study.
List view / Grid view
Roche
news
Anti-amyloid antibody receives Breakthrough Therapy Designation in US
Roche's gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer’s disease patients.
news
Ronapreve™ reduces COVID-19 viral load within seven days
Phase II/III trial shows Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19, complimenting previous findings.
news
Babies with SMA able to swallow with Evrysdi® treatment
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were able to swallow and feed orally after 12 months of treatment.
news
Roche to acquire TIB Molbiol Group to expand PCR-test portfolio
Roche signs a definitive share purchase agreement with TIB Molbiol Group to expand PCR-test portfolio against infectious diseases.
news
MHRA approve first monoclonal antibody treatment for COVID-19
The MHRA have approved Ronapreve as the first monoclonal antibody combination product for the treatment of COVID-19 infection in the UK.
news
Parkinson’s disease market sales to reach $11.5 billion in 2029
The Parkinson’s disease market is set to triple in sales by 2029 driven by novel biologics and delivery systems, reports GlobalData.
news
Roche’s Evrysdi significantly improves lives of babies with SMA
The Phase II study of Evrysdi showed significant improvements in survival and motor milestones in babies with type 1 spinal muscular atrophy (SMA).
news
Bayer appoints Head of Research and Early Development for Oncology
Bayer have announced that Professor Dominik Ruettinger will be its new Head of Research and Early Development for Oncology, effective 1 October 2021.
news
2021 a pivotal year for personalised neoantigens, says GlobalData
With multiple catalysts coming up in late 2021, GlobalData reports a boom in the field of personalised neoantigen immuno-oncology therapeutics.
article
Building the UK’s domestic pharma manufacturing capability
In this article, Rich Quelch, Global head of marketing at Origin, discusses how the UK’s pharmaceutical supply chain could be adapted to increase its resilience to future disruptions and the challenges in doing so.
news
New group to tackle data governance and guide digital transformation in pharma
The Pistoia Alliance's Data Governance Community of Interest will develop best practices and advance digital transformation in the pharma/life sciences industry.
news
Evrysdi™ approved for treatment of spinal muscular atrophy in Europe
The European Commission has granted marketing authorisation to Roche’s Evrysdi™ (risdiplam) as a treatment for spinal muscular atrophy in infants, children and adults.
news
NICE approves olaparib and bevacizumab for use on the Cancer Drugs Fund
The recommendation will allow more data to be collected about the combination treatment while allowing patients with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer to access the medication.